Novo CEO blasts ‘mass compounding’ of GLP-1 drugs as safety battle escalates Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine FDA oversight as legal battle escalates. Original Source: https://www.foxbusiness.com/media/novo-ceo-blasts-mass-compounding-glp-1-drugs-safety-battle-escalates
